Lupin Acquires Huminsulin Portfolio From Lilly To Strengthen Diabetes Care

Global pharmaceutical leader Lupin has acquired the Huminsulin range in India from Eli Lilly and Company (Lilly). This strategic move is aimed at bolstering Lupin’s diabetes care portfolio and enhancing its reach in the treatment of diabetes.

The Huminsulin range, which includes Insulin Human formulations such as Huminsulin R, Huminsulin NPH, Huminsulin 50/50, and Huminsulin 30/70, has been marketed by Lupin in India under existing Distribution and Promotion Agreements with Lilly. These products are prescribed for managing blood sugar levels in patients with type 1 and type 2 diabetes mellitus, benefiting both adults and children.

Diabetes remains a major health challenge in India, with a significant population requiring insulin therapy. While insulin is a critical component of type 1 diabetes management, it also becomes essential in type 2 diabetes as the disease progresses. The acquisition of Huminsulin positions Lupin to better serve this growing need.

“This acquisition is a strategic step towards expanding our diabetes care portfolio and providing high-quality, affordable healthcare to our patients,” said Nilesh Gupta, Managing Director of Lupin. “It underscores our dedication to combating diabetes and delivering comprehensive care solutions.”

Rajeev Sibal, President of India Region Formulations at Lupin, added, “Lupin has consistently led in offering holistic diabetes care. The addition of Huminsulin further strengthens our capabilities, allowing us to provide a wide range of human insulin options to millions of patients and help them lead healthier lives.”

With this acquisition, Lupin solidifies its position as a leader in diabetes management, reinforcing its commitment to addressing the growing burden of the disease in India.